$SNWV News

Last published 1d ago

1d agoSNWVSANUWAVE Health, Inc. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
1d agoSNWVSanuwave Announces Q3 FY2026 Financial ResultsGlobeNewswire
5d agoSNWVSanuwave Will Host a Conference Call on November 11, 2026 at 8:30 AM (ET) to Present Q3 2026 Financial ResultsGlobeNewswireEDEN PRAIRIE, Minn., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave") (NASDAQ:SNWV), a leading provider of next-generation FDA-approved wound care products, will
5d agoSNWVSanuwave Will Host a Conference Call on November 11, 2026 at 8:30 AM (ET) to Present Q3 2026 Financial ResultsGlobeNewswireSanuwave Will Host a Conference Call on November 11, 2026 at 8:30 AM (ET) to Present Q3 2026 Financial Results...
6d agoSNWVSanuwave Health Comments on 2027 Medicare Physician Fee Schedule Rate for UltramistGlobeNewswireCMS establishes $314.54 reimbursement rate for CPT code 97610 for 2027, an approximately 21% reduction vs 2026 rate of $397.81 2027 Hospital outpatient rate for 97610 code set at $235.04, an approximately 15% increase
3mo agoSNWVSanuwave Announces Q2 FY2026 Financial ResultsGlobeNewswireQ2 2026 revenues were $9.7 million, down 3% from $10.1 million in Q2 2025. Q2 2026 gross margin was 76.2%, versus 78.1% in Q2 2025. GAAP Operating (Loss) Income was $(0.3) million for Q2 2026 versus $1.4
3mo agoSNWVSanuwave Will Host a Conference Call on August 7, 2026 at 8:30 AM (ET) to Present Q2 2026 Financial ResultsGlobeNewswireEDEN PRAIRIE, Minn., July 30, 2026 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave") (NASDAQ:SNWV), a leading provider of next-generation FDA-approved wound care products, will
4mo agoSNWVSanuwave Health Reports Preliminary Q2 2026 Revenue of $9.6–$9.8 Million, Above High End of Revised GuidanceGlobeNewswireEDEN PRAIRIE, Minn., July 13, 2026 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave") (NASDAQ:SNWV), a leading provider of FDA-cleared directed energy systems used in advanced
4mo agoSNWVSanuwave Health Updates Second Quarter 2026 GuidanceGlobeNewswireSanuwave updates guidance for Q2 2026 to $8.5 - $9.5 million Company on pace for record unit sales of applicators in Q2 Market disruption impacting Ultramist system sales EDEN PRAIRIE, Minn., June 16, 2026 (GLOBE
6mo agoSNWVSanuwave Announces Revenues and Financial Results for Q1 FY2026GlobeNewswireQ1 2026 revenues were $9.6 million, up 3.1% from $9.3 million in Q1 2025. This represents the highest Q1 quarterly revenues in Company history. Q1 2026 gross margin was 77.3%, versus 79.0% in Q1 2025. GAAP Operating
6mo agoSNWVSanuwave Will Host a Conference Call on May 13, 2026 at 8:30 AM (ET) to Present Q1 2026 Financial ResultsGlobeNewswireEDEN PRAIRIE, Minn., May 06, 2026 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave") (NASDAQ:SNWV), a leading provider of next-generation FDA-approved wound care products, will host a
6mo agoSNWVSanuwave Health Reports Preliminary Q1 2026 Revenue of $9.6–$9.7 Million, Up 3-4% Year-over-YearGlobeNewswireSanuwave is pleased to announce preliminary revenues of $9.6 million to $9.7 million for the first quarter ended March 31, 2026, in line with prior guidance for Q1. EDEN PRAIRIE, Minn., April 16, 2026 (GLOBE NEWSWIRE)
7mo agoSNWVSanuwave Announces Record Revenues and Financial Results for Q4 and Full Year 2025GlobeNewswireQ4 2025 revenues were $13.4 million, up 29.7% from Q4 2024. This was an all-time quarterly record for the Company. Full year 2025 revenues were $44.1 million up 35.0% from full year 2024 revenues. This was an all-time
10mo agoSNWVSanuwave Health Announces Preliminary Q4 2025 Revenue of $13.3–$13.4 Million, Up 29–30% Year-over-Year; Achieves Record Quarterly and Full-Year RevenueGlobeNewswireSanuwave is pleased to announce preliminary revenues of $13.3 million to $13.4 million for the fourth quarter ended December 31, 2025. This represents the highest quarterly revenues in Company history. Q4 2025 revenue
11mo agoSNWVSanuwave to Participate in the 44th Annual J.P. Morgan Healthcare ConferenceGlobeNewswireEDEN PRAIRIE, Minn., Dec. 10, 2025 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave") (NASDAQ:SNWV), a leading provider of FDA-approved next-generation wound care products, is pleased
11mo agoSNWVSanuwave Announces the Addition of UltraMIST to Healogics Group Purchasing Organization (GPO), iSupplyGlobeNewswireHealogics Wound Care Supply adds UltraMIST to its Group Purchasing Organization Healogics iSupply and Sanuwave collaborate to provide UltraMIST as an option for GPO members EDEN PRAIRIE, Minn., Dec. 08, 2025 (GLOBE
1y agoSNWVSanuwave Announces Q3 FY2025 Financial ResultsGlobeNewswireQ3 2025 revenues were $11.5 million, up 22% from $9.4 million in Q3 2024. This represents the highest quarterly revenues in Company history. Q3 2025 gross margin was 77.9%, versus 75.5% in Q3 2024. GAAP Operating
1y agoSNWVSanuwave Will Host a Conference Call on November 7, 2025 at 8:30 AM (ET) to Present Q3 2025 Financial ResultsGlobeNewswireEDEN PRAIRIE, Minn., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave") (NASDAQ:SNWV), a leading provider of next-generation FDA-approved wound care products, will host a
1y agoSNWVCMS Publishes Final Rule for Calendar Year 2026 Physician Fee Schedule for UltraMIST Procedure (CPT code 97610)GlobeNewswireCMS adopts Final Rule for 2026 Physician Fee Schedule in line with proposed rule for CPT code 97610 2026 rates for physician offices, home visits, long-term care, and hospitals are in line with the proposed rule and
1y agoSNWVSanuwave Health Announces Preliminary Revenue Results for the Third Quarter 2025 (Ended September 30, 2025)GlobeNewswireSanuwave announces preliminary revenues of $11.4 million to $11.6 million for the third quarter ended September 30, 2025. This represents the highest quarterly revenues in Company history. Q3 2025 revenue increased
1y agoSNWVSanuwave Announces Strategic Debt Refinancing with New Credit FacilityGlobeNewswireCredit facility from J.P. Morgan consists of a four-year term loan of $23 million and a two-year $5 million revolving credit facility backed by accounts receivable Both the term loan and revolver have an interest rate of SOFR +350bp
1y agoSNWVSANUWAVE Health, Inc. (SNWV) Q2 2025 Earnings Call TranscriptEarnings Call Transcripts
1y agoSNWVSanuwave Announces Q2 FY2025 Financial ResultsGlobeNewswireQ2 2025 revenues were $10.2 million, up 42% from $7.2 million in Q2 2024. This represents the highest Q2 quarterly revenues in Company history. Q2 2025 gross margin was 78.3%, versus 73.2% in Q2 2024. GAAP Operating
1y agoSNWVSanuwave Will Host a Conference Call on August 8, 2025 at 8:30 AM (ET) to Present Q2 2025 Financial ResultsGlobeNewswireEDEN PRAIRIE, Minn., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave") (NASDAQ:SNWV), a leading provider of next-generation FDA-approved wound care products, will host a
1y agoSNWVSanuwave Health to Present at Canaccord Genuity Growth ConferenceGlobeNewswireEDEN PRAIRIE, Minn., July 22, 2025 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (NASDAQ:SNWV), a leading provider of next-generation, FDA-approved wound care products , today announced, that Morgan Frank, Chief Executive
1y agoSNWVSanuwave Health Announces Preliminary Revenue Results for the Second Quarter 2025 (Ended June 30, 2025)GlobeNewswireSanuwave is pleased to announce preliminary revenues of $10.1 million to $10.2 million for the second quarter ended June 30, 2025. This represents the highest Q2 quarterly revenues in Company history. Q2 2025 revenue
1y agoSNWVSanuwave Health Appoints Industry Veteran Dustin Libby as Executive Vice President of Commercial OperationsGlobeNewswireEDEN PRAIRIE, Minn., June 03, 2025 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave") (NASDAQ:SNWV), a leading provider of next-generation FDA-approved wound care products, is pleased
1y agoSNWVSanuwave Health Selected for Inclusion in Russell 2000® IndexGlobeNewswireEDEN PRAIRIE, Minn., May 28, 2025 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (NASDAQ:SNWV), a leading provider of next-generation, non-invasive wound care solutions, today announced, as part of the 2025 Russell indexes
1y agoSNWVSanuwave Health Appoints Greg Bazar to Board of DirectorsGlobeNewswireEDEN PRAIRIE, Minn., May 28, 2025 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave") (NASDAQ:SNWV), a leading provider of next-generation FDA-approved wound care products, is pleased to
1y agoSNWVSanuwave Announces Q1 FY2025 Financial ResultsGlobeNewswireQ1 2025 revenues were $9.3 million, up 61% from $5.8 million in Q1 2024. This represents the highest Q1 quarterly revenues in Company history. Q1 2025 gross margin was 79.0%, versus 72.6% in Q1 2024. GAAP Operating
1y agoSNWVSanuwave Will Host a Conference Call on May 9, 2025 at 8:30 AM (ET) to Present Q1 2025 Financial ResultsGlobeNewswireEDEN PRAIRIE, Minn., May 05, 2025 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave") (NASDAQ:SNWV), a leading provider of next-generation FDA-approved wound care products, will host a
1y agoSNWVSANUWAVE Health Announces Preliminary Revenue Results for the First Quarter 2025 (Ended March 31, 2025)GlobeNewswireSANUWAVE is pleased to announce preliminary revenues of $9.1 million to $9.3 million for the first quarter ended March 31, 2025. This represents the highest Q1 quarterly revenues in Company history. Q1 2025 revenue
1y agoSNWVSANUWAVE Announces Record Quarterly Revenues: Q4 FY2024 Financial ResultsGlobeNewswireQ4 2024 revenues were $10.3 million, up 47% from Q4 2023. This was an all-time quarterly record for the Company. Full year 2024 revenues were $32.6 million, up 60% from full year 2023 revenues. This was an all-time
1y agoSNWVSANUWAVE Will Host a Conference Call on March 21, 2025 at 8:30 AM (ET) to Present Q4 and Full Year 2024 Financial ResultsBusiness WireSANUWAVE Health, Inc. (the "Company" or "SANUWAVE") (NASDAQ:SNWV), a leading provider of next-generation FDA-approved wound care products, will host a live conference call on Friday, March 21, 2025, at 8:30
1y agoSNWVSanuwave Health to Uplist to the Nasdaq Global MarketGlobeNewswireEDEN PRAIRIE, Minn., March 04, 2025 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave") (OTCQB:SNWV), a leading provider of next-generation FDA-approved wound care products, announced today that
1y agoSNWVSANUWAVE Health to Participate in 37th Annual Roth ConferenceGlobeNewswireEDEN PRAIRIE, Minn., Feb. 19, 2025 (GLOBE NEWSWIRE) -- SANUWAVE Health, Inc. (OTCQB:SNWV), a leading provider of next-generation FDA-approved wound care products, today announced that Morgan Frank, Chief Executive
2y agoSNWVSANUWAVE Announces Record Quarterly Revenues: Q3 FY2024 Financial ResultsGlobeNewswireQ3 2024 revenues were $9.4 million, up 89% from Q3 2023. This was an all-time quarterly record for the Company. Q3 2024 gross margin was 75.5%, vs 71.5% in Q3 2023 GAAP Operating Income was $2.0 million Company
2y agoSNWVSANUWAVE Will Host a Conference Call on November 8, 2024 at 8:30 AM (ET) to Present Q3 Financial ResultsGlobeNewswireEDEN PRAIRIE, Minn., Nov. 04, 2024 (GLOBE NEWSWIRE) -- SANUWAVE Health, Inc. (the "Company" or "SANUWAVE") (OTCQB:SNWV), a leading provider of next-generation FDA-approved wound care products, will host a
2y agoSNWVSANUWAVE Announces Reverse Stock Split, Note and Warrant Exchange, and PIPE OfferingGlobeNewswire1-for-375 reverse stock split effective at market open today Exchanged $43.2 million in principal amount of convertible notes and warrants previously exercisable for approximately 1.7 billion pre-split shares for
2y agoSNWVSANUWAVE Health Announces 1-For-375 Reverse Stock SplitGlobeNewswireCommon Stock Will Begin Trading on a Split-adjusted Basis on October 18, 2024 EDEN PRAIRIE, Minn., Oct. 16, 2024 (GLOBE NEWSWIRE) -- SANUWAVE Health, Inc. (the "Company" or "SANUWAVE") (OTCQB:SNWV), a leading
2y agoSNWVSANUWAVE Announces Record Quarterly Revenues: Q2 FY2024 Financial ResultsGlobeNewswireQ2 2024 revenues were $7.2 million, up 53% from Q2 2023. This was an all-time quarterly record for the Company. Q2 2024 Gross Margin was 73%, vs 74% in Q2 2023 GAAP Operating Income was $2.0 Million
2y agoSNWVSANUWAVE Will Host a Conference Call on August 13, 2024 at 8:30 AM (ET) to Present Q2 Financial ResultsGlobeNewswireEDEN PRAIRIE, MN, Aug. 07, 2024 (GLOBE NEWSWIRE) -- SANUWAVE Health, Inc. (the "Company" or "SANUWAVE") (OTCQB:SNWV), a leading provider of next-generation FDA-approved wound care products, will host a live
2y agoSNWVSANUWAVE Health Announces Preliminary Revenue Results for the First Quarter 2024 (Ended March 31, 2024)GlobeNewswireSANUWAVE is pleased to announce preliminary revenues of $5.7 million to $5.9 million for the first quarter ended March 31, 2024. This represents the highest Q1 revenues in company history. Q1 2024 revenue increased
2y agoSNWVSANUWAVE Health Appoints Industry Veteran Peter Sorensen as Chief Financial OfficerGlobeNewswireSorensen brings strong finance, forecasting, analysis, and capital markets experience as well as abilities in software, process automation, and human resources to SANUWAVE EDEN PRAIRIE, MN, April 01, 2024
2y agoSNWVSANUWAVE Announces Record Q4 and FY2023 RevenueGlobeNewswireQ4 2023 revenues were a record $7.0 million, up 27% from Q4 2022 FY 2023 revenues were a record $20.4 million, up 22% from FY2022 Operating income was $1 million for Q4 2023 compared to an operating loss of $1.5
2y agoSNWVSANUWAVE Will Host a Conference Call on March 22, 2024 at 8:30 AM (ET) to Present the Q4 and FY2023 Financial ResultsGlobeNewswireEDEN PRAIRIE, MN, March 20, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – SANUWAVE Health, Inc. (the "Company" or "Sanuwave") (OTCQB:SNWV), a leading provider of next-generation FDA-approved wound care
2y agoSNWVSANUWAVE Health Reports Stockholder Approval of SEPA Merger at Special Meeting of StockholdersGlobeNewswireAt a special meeting of stockholders on February 21, 2024, SANUWAVE stockholders approved the business combination with SEP Acquisition Corp. by a vote of 798,379,869 "for" and 5,221,765 "against" with 71,525 abstaining
2y agoSNWVSANUWAVE Announces Special Meeting of Stockholders to Vote on Business Combination with SEP Acquisition Corp. (Nasdaq: SEPA)GlobeNewswireEDEN PRAIRIE, MN, Jan. 22, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – SANUWAVE Health, Inc. (the "Company" or "SANUWAVE") (OTCQB:SNWV), a leading provider of next-generation FDA-approved wound care
2y agoSNWVSANUWAVE Health Announces Preliminary Revenue Results for the Fourth Quarter and Fiscal Year 2023, Ended December 31, 2023GlobeNewswireSANUWAVE is pleased to announce preliminary revenues of $6.6 million to $6.8 million for the fourth quarter ended December 31, 2023. This represents a new quarterly revenue record for the Company. Q4 2023 revenue
3y agoSNWVSANUWAVE Announces Q3 2023 Financial ResultsGlobeNewswireEDEN PRAIRIE, MN,, Nov. 10, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – SANUWAVE Health, Inc. (the "Company" or "SANUWAVE") (OTCQB:SNWV), a leading provider of next-generation FDA-approved wound care products, today